Visceral steatosis, congenital
MONDO:0009220Also known as: visceral steatosis, congenital, White liver disease, fatal neonatal hepatic steatosis, fatty liver disease, congenital, fatty metamorphosis of viscera, steatosis of liver, visceral steatosis
8 clinical trials for this condition and its sub-types, 5 tagged with Visceral steatosis, congenital itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Could a common sugar fuel liver damage?
Knowledge-focused Recruiting nowThis trial asks whether fructose, a sugar found in fruit and processed foods, causes more liver inflammation in people with MASH (a serious fatty liver disease) than in those with milder fatty liver or no liver disease. Over four weeks, participants follow a low-sugar diet and th…
Sponsor: Queen Mary University of London • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Fatty liver frailty: do men and women differ?
Knowledge-focused Recruiting nowThis observational study aims to see if frailty—a state of increased weakness and vulnerability—differs between men and women with MASLD (fatty liver disease). Researchers will track 140 participants over time using physical tests and questionnaires. No drugs or treatments are be…
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New drug tested in patients with fatty liver and cirrhosis
Knowledge-focused Recruiting nowThis early-stage study tests a single dose of an experimental drug called efimosfermin alfa in 32 adults with fatty liver disease and varying degrees of liver damage. The goal is to see how the drug moves through the body and whether it is safe. Participants must have liver cirrh…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC